211 related articles for article (PubMed ID: 12001033)
1. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.
Smith KY
J Infect Dis; 2002 May; 185 Suppl 2():S123-7. PubMed ID: 12001033
[TBL] [Abstract][Full Text] [Related]
2. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
3. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
Holstein A; Plaschke A; Egberts EH
Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
[TBL] [Abstract][Full Text] [Related]
4. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
Falutz J
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
[TBL] [Abstract][Full Text] [Related]
5. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.
Samaras K
J Antimicrob Chemother; 2008 Feb; 61(2):238-45. PubMed ID: 18070830
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
Leonard EG; McComsey GA
Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
[TBL] [Abstract][Full Text] [Related]
7. [Metabolic disorders and lipodystrophy. Adverse effects of antiretroviral therapy].
Goebel FD; Westner I
MMW Fortschr Med; 2001 Apr; 143 Suppl 1():40-4. PubMed ID: 11373778
[TBL] [Abstract][Full Text] [Related]
8. Lactic acidosis in HIV patients receiving highly active antiretroviral therapy.
Chow YW; Leong CL; Chow HL; Hooi LS
Med J Malaysia; 2007 Mar; 62(1):78-80. PubMed ID: 17682581
[TBL] [Abstract][Full Text] [Related]
9. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
Calza L; Manfredi R; Chiodo F
J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
[TBL] [Abstract][Full Text] [Related]
10. Highly active antiretroviral HIV therapy-associated fatal lactic acidosis: quantitative and qualitative mitochondrial DNA lesions with mitochondrial dysfunction in multiple organs.
Thoden J; Lebrecht D; Venhoff N; Neumann J; Müller K; Walker UA
AIDS; 2008 May; 22(9):1093-4. PubMed ID: 18520357
[No Abstract] [Full Text] [Related]
11. Use of Tris-hydroxymethyl aminomethane in severe lactic acidosis due to highly active antiretroviral therapy: a case report.
Marfo K; Garala M; Kvetan V; Gasperino J
J Clin Pharm Ther; 2009 Feb; 34(1):119-23. PubMed ID: 19125910
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of protease inhibitor therapy.
Bernasconi E
AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115
[TBL] [Abstract][Full Text] [Related]
13. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
[TBL] [Abstract][Full Text] [Related]
14. Metabolic complications of antiretroviral therapy.
Sweet DE
Top HIV Med; 2005; 13(2):70-4. PubMed ID: 16082057
[TBL] [Abstract][Full Text] [Related]
15. HAART-associated body habitus and metabolic changes, Part 2.
Liss M; Boyle BA
AIDS Read; 2000 Dec; 10(12):688-91. PubMed ID: 11189733
[No Abstract] [Full Text] [Related]
16. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.
Dubé MP; Stein JH; Aberg JA; Fichtenbaum CJ; Gerber JG; Tashima KT; Henry WK; Currier JS; Sprecher D; Glesby MJ; ;
Clin Infect Dis; 2003 Sep; 37(5):613-27. PubMed ID: 12942391
[No Abstract] [Full Text] [Related]
17. Evidence for mitochondrial toxicity: lactic acidosis as proof of concept.
Brinkman K
J HIV Ther; 2001 Mar; 6(1):13-6. PubMed ID: 11501196
[No Abstract] [Full Text] [Related]
18. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic consideration for the use of antiretroviral agents in the elderly.
Rhee MS; Greenblatt DJ
J Clin Pharmacol; 2008 Oct; 48(10):1212-25. PubMed ID: 18812611
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
